Abnormal activation of the mammalian target of rapamycin (mTOR) pathway plays a critical role in LAM pathogenesis by promoting cell proliferation, which may increase susceptibility to malignancies in these patients. Here, MTOR is linked to lymphangioleiomyomatosis.